Literature DB >> 10027927

Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding.

S Youssef1, D T Nguyen, T Soulis, S Panagiotopoulos, G Jerums, M E Cooper.   

Abstract

BACKGROUND: Advanced glycation end-products (AGEs) have been implicated in the pathogenesis of diabetic nephropathy, and aminoguanidine (AG) has been shown to decrease the accumulation of AGEs in the diabetic kidney.
METHODS: This study investigates changes in AGE binding associated with diabetes in the rat kidney using in vitro and in vivo autoradiographic techniques. Male Sprague-Dawley rats were randomized into control and diabetic groups with and without AG treatment and were sacrificed after three weeks. Frozen kidney sections (20 microm) were incubated with [125I]-AGE-RNase or [125I]-AGE-BSA. To localize the AGE binding site, in vivo autoradiography was performed by injection of 15 microCi of [125I]-AGE-BSA into the abdominal aorta of the rat.
RESULTS: Low-affinity binding sites specific for AGEs in the renal cortex (IC50 = 0.28 microm) were detected by in vitro autoradiography. There was a significant increase in [125I]-AGE binding in the diabetic kidney, which was prevented by AG treatment. Emulsion autoradiography revealed that binding was localized primarily to proximal tubules in the renal cortex. Renal AGE levels, as assessed by fluorescence or by radioimmunoassay, were increased after three weeks of diabetes. This increase was attenuated by AG therapy.
CONCLUSIONS: AGE binding sites are present within the proximal tubules of the kidney and appear to be modulated by endogenous AGE levels. It remains to be determined if these binding sites represent receptors involved in clearance of AGEs or are linked to pathogenic pathways that lead to the development of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027927     DOI: 10.1046/j.1523-1755.1999.055003907.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  Albumin and glycated albumin activate KIM-1 release in tubular epithelial cells through distinct kinetics and mechanisms.

Authors:  Ai Ing Lim; Loretta Y Y Chan; Sydney C W Tang; Kar Neng Lai; Joseph C K Leung
Journal:  Inflamm Res       Date:  2014-07-26       Impact factor: 4.575

3.  Aminoguanidine reduces diabetes-associated cardiac fibrosis.

Authors:  Fernando Magdaleno; Chuck Christopher Blajszczak; Claudia Lisette Charles-Niño; Alma Marlene Guadrón-Llanos; Alan Omar Vázquez-Álvarez; Alejandra Guillermina Miranda-Díaz; Natalia Nieto; María Cristina Islas-Carbajal; Ana Rosa Rincón-Sánchez
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

4.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).

Authors:  M D Oldfield; L A Bach; J M Forbes; D Nikolic-Paterson; A McRobert; V Thallas; R C Atkins; T Osicka; G Jerums; M E Cooper
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  RAGE-NF-κB-PPARγ Signaling is Involved in AGEs-Induced Upregulation of Amyloid-β Influx Transport in an In Vitro BBB Model.

Authors:  Fang Chen; Arijit Ghosh; Mei Hu; Yan Long; Hongbin Sun; Lingyi Kong; Hao Hong; Susu Tang
Journal:  Neurotox Res       Date:  2017-09-04       Impact factor: 3.911

Review 6.  New potential agents in treating diabetic kidney disease: the fourth act.

Authors:  Mark E Williams
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.

Authors:  Mark E Williams
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

8.  Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.

Authors:  Daniel P K Ng; Charles L Hardy; Wendy C Burns; Evelyne E Muggli; Nicole Kerr; Jane McCausland; Daine Alcorn; Timothy E Adams; Jeffrey D Zajac; Richard G Larkins; Marjorie E Dunlop
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

Review 9.  Can we target tubular damage to prevent renal function decline in diabetes?

Authors:  Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

10.  Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat.

Authors:  B J Davis; J M Forbes; M C Thomas; G Jerums; W C Burns; H Kawachi; T J Allen; M E Cooper
Journal:  Diabetologia       Date:  2003-11-29       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.